Background We wished to assess the respective roles of the antihypertensive and blood pressure (BP)-independent effects of antihypertensive drugs on arterial hemodynamics and left ventricular hypertrophy (LVH) in end-stage renal disease (ESRD) patients.
(P<.01). At baseline, the two groups had LVH mostly due to increased LV end-diastolic diameter (LVEDD) (perindopril, 54.3+1.4 and nitrendipine, 54.3±2.4 mm) with near-normal mean LV wall thickness (perindopril, 11 .4+0.3 and nitrendipine, 11 .2+0.4 mm). A decrease in LVM was observed only in patients receiving perindopril (from 317±t18 to 247±21 g) (time-treatment interaction, P=.036). Nitrendipine had no significant effect on LVM (314±29 versus 286±32 g). The decrease in LVM observed with perindopril was associated with a reduction in LVEDD (49.9±1.6 versus 54.3±1.4 mm after 12 months) (time-treatment interaction, P=.04), while the mean LV wall thickness was unchanged (11.4+0.3 versus 10.5±0.5 mm). Cardiac alterations were not correlated with changes in BP or with alterations in plasma renin activity or aldosterone or catecholamine levels.
Conclusions In ESRD patients with LVH, ACE inhibition decreases LVM independently of its antihypertensive effect and of associated alterations in arterial hemodynamics. The decrease in LVM was due primarily to a decrease in LV volume, which may have resulted in these patients from chronic volume overload. (Circulation. 1994; 90:2786 -2796 Key Words * perindopril * nitrendipine * arteries . hypertrophy * kidney diuretics or peripheral vasodilators.2-4 LVH is the most common cardiac alteration observed in end-stage renal disease (ESRD) patients5 and is also a predictor of cardiac death in hemodialysis patients. 6 Even though hypertension was considered the principal risk factor, LVH developed and progressed with time on hemodialysis, with only a weak correlation to blood pressure (BP).7 In uremic animals, LVH developed despite BP normalization by ACE inhibitors, a-and a-blockade, or diuretics,8 and the impact of antihypertensive agents on LV mass in ESRD patients is virtually unknown. 9 The dominant factor relating BP to LVH is endsystolic stress.10 This parameter is influenced by the geometrical properties of the left ventricle and endsystolic pressure. End-systolic pressure is critically dependent on physical properties of the arterial system (its geometry and distensibility), which determine the pulse wave velocity (PWV) and the intensity and timing of arterial wave reflections (AWR).1" Increased aortic PWV and increased effect of AWR have been observed in ESRD patients12,13 and were directly related to the magnitude of the LVH,14 underlining the importance of alterations in large-artery hemodynamics in the devel-opment of LVH in these patients. Therefore, since the pressure load on the heart is related not only to increased vascular resistance but also to changes in aortic compliance and the timing and intensity of wave reflections, all these parameters should be taken into account when analyzing the effect of antihypertensive drugs on LVM and the respective roles of hemodynamic and nonhemodynamic factors. Such studies have been performed only rarely in essential hypertension15 and have never been performed in hypertensive ESRD patients. We therefore conducted a 1-year randomized, double-blind trial to compare the effects of an ACE inhibitor, perindopril, and a calcium channel blocker, nitrendipine, on BP, arterial hemodynamics (including peripheral resistance, arterial compliance, and AWR), and LVM in hypertensive ESRD patients with LVH.
Methods

Subjects
The study involved stable ESRD patients treated by hemodialysis whose median predialysis BP for the 6 months preceding their inclusion was >160/95 mm Hg. Inclusion criteria included absence of acute myocardial infarction, valvular heart disease, cerebral vascular disease, or decompensated heart failure and adequate echocardiographic study demonstrating LVH according to Penn convention criteria, ie, LVM >134 g/m' in men and >110 g/m' in women. 16 Thirty-two patients met the eligibility criteria and were included. Seven patients were already on antihypertensive therapy, receiving /-blocking drugs alone or in combination with vasodilators. In these patients, the current antihypertensive medication was progressively reduced over 1 week, and a 6-week placebo period was begun. Patients not receiving antihypertensive medication began the placebo run-in period directly. After this run-in placebo period, patients were divided into two groups of 16 according to a randomization list. The clinical, hemodynamic, and laboratory screening of these patients at baseline (after the placebo run-in period) and during the remainder of the study was performed before the first weekly hemodialysis. Patients were dialyzed three times per week on polyacrylonitrile (AN 69, Hospal) or cellulose acetate membranes (Nipro, Nissho Corp), and the duration of hemodialysis was 4 to 5 hours. Dialysate was delivered by a system including bicarbonate delivery, adjustable sodium concentration, and controlled ultrafiltration. Patients were weighed in light clothing, without shoes, on an electronic scale with a precision of ± 100 g before and after each dialysis. Patient "dry weight" was defined as the body weight below which, in a normoalbuminemic patient, hypotension or muscle cramps occur and postural hypotension is clinically manifest. Interdialytic body weight changes (ABW, in kilograms) were determined as the difference between the "dry weight" and predialytic weight. No antihypertensive substances other than perindopril or nitrendipine were allowed. Compliance with treatment was determined by a pill count at each visit during the trial. Each patient provided informed written consent before participating in the protocol previously approved by our institutional review board.
Drug Selection and Study Design
Because calcium channel blockers are the most frequently prescribed antihypertensive drugs in ESRD patients on hemodialysis,17 nitrendipine, a 1,4-dihydropyridine derivative, was chosen as the reference drug. The absorption, elimination, and metabolism of nitrendipine are not altered by renal insufficiency or hemodialysis. 18 The hypotensive effect of a single oral dose of nitrendipine begins within 30 minutes, is greatest within 1.5 hours (tma. is 1.5±0.33 hours in ESRD patients), and lasts for 8 to 24 hours. 19 The usual therapeutic regimen for achieving satisfactory and stable BP control in ESRD patients is 20 mg PO twice daily.20 Perindopril is a nonsulfhydryl ACE inhibitor that is deesterified to its active metabolite perindoprilat. Renal failure alters the pharmacokinetics of perindoprilat, and both perindopril and perindoprilat are poorly protein-bound and eliminated to a major extent by hemodialysis.2' The study of the effects of hemodialysis on the pharmacokinetics of perindoprilat after short-and long-term perindopril treatment has shown that a dose of 2 mg of perindopril given after each hemodialysis session (3 times weekly) ensures satisfactory BP control, stable perindoprilat concentration, a high degree of ACE inhibition, and good tolerance.22 Maximum perindoprilat serum concentration is achieved after 20 hours and remains stable during the interdialytic interval. Hemodialysis induces a 55% to 66% decrease in serum perindoprilat concentration. A maximum inhibition of ACE activity of 93% to 95% is reached within 20 hours after oral administration and persists during the interdialytic interval; residual inhibition measured after hemodialysis was 75% to 78%.22 After randomization at day 0 (baseline), patients received either 20 mg nitrendipine once daily or perindopril 2 mg after each hemodialysis session (3 times weekly). Perindopril was presented similarly to nitrendipine, ie, in blister packs containing 7 pills (1 week of treatment). Only the pills corresponding to the day of hemodialysis contained perindopril; the other pills contained placebo. Patients were instructed to take the tablets at 8 AM (or after dialysis the days of hemodialysis sessions). After 6 weeks of treatment, the BP was measured before hemodialysis at 7 AM, ie, 24 hours after the last dose of nitrendipine or 60 hours after the last dose of perindopril (given after the last hemodialysis session of the previous week). If the predialysis diastolic BP (DBP) exceeded 95 mm Hg, the dose of nitrendipine was increased to 40 mg daily (2x20 mg) and that of perindopril to 4 mg the day of hemodialysis. Patients on nitrendipine were instructed to take their medication at 8 AM (or after dialysis the days of a hemodialysis session) and 8 PM. Patients on perindopril received the same instructions, but the perindopril was present only in the evening pills of the days of hemodialysis. Subsequent visits with sphygmomanometric BP measurements and hemodynamic study were scheduled for after 3, 6, 9, and 12 months of treatment; during these visits, patients whose predialysis DBP was >95 mm Hg were withdrawn from the study. Because of the differences in pharmacokinetics and drug prescription schedule, the efficacy of the two drugs on BP control was evaluated during the interdialytic period by noninvasive ambulatory BP monitoring with a DIASYS 200, NOVACOR ECG-gated auscultatory device that has been validated according to British Hypertension Society protocol. 23 The monitor was placed on the arm without the arteriovenous fistula before the dialysis session. Measurements were started 15 minutes before the start of the dialysis session, continued during the interdialytic period, and terminated before the start of the subsequent hemodialysis session, ie, after 48 hours. The monitor was programmed to measure BP every 15 minutes.
Recordings were included in the analysis only if at least 80% of the expected measurements were available. Readings of pulse pressure <15 mm Hg and diastolic BP >150 mm Hg were rejected.24 The BP monitoring was performed without warning and in random order during the first interdialytic interval of the week. The following parameters were analyzed: average interdialytic systolic, diastolic, and mean BPs and their SDs. A checklist was used to inquire about adverse drug reactions, and all symptoms were evaluated blindly after completion of the study.
BP and Arterial Parameters
Investigations were performed in a controlled environment kept at 22+2°C. Brachial artery BP was measured with a mercury sphygmomanometer with cuffs adapted to arm circumference after the subjects had been recumbent for at least 15 minutes. Systolic BP (SBP) was taken at phase I of the Korotkoff sounds and DBP at phase V. Mean BP (MBP) was determined as MBP=DBP+[(SBP-DBP)/31. BP was measured every 5 minutes for half an hour, and the average of these BPs was determined. BP was measured before and after the hemodialysis session. Arterial PWV PWV was determined by the foot-to-foot method as previously described.12 Transcutaneous Doppler flow recordings were carried out simultaneously at the carotid and femoral arteries (aortic PWV), at the carotid and radial arteries (arm PWV), and at the femoral and dorsalis pedis arteries (leg PWV) with a Doppler M842 8 MHz (SEGA) and an 8188 Gould recorder at 200 mm/s. PWV was calculated as the distance between recording sites measured over the surface of the body divided by the time delay measured between the feet of the flow waves.12,25 The time delay was averaged over 10 to 15 cardiac cycles. The variability was 4±1% for aortic PWV, 6±+2% for arm PWV, and 5.1±1.5% for leg PWV. The transmission ratio (TR) of PWV was calculated as25 TR= (arm PWV/aortic PWV)1'2.
Aortic Diameter Determination
The diameter of the aorta at the bifurcation (AoDbif) was measured with a CGR Sonel 300 echograph (Compagnie Generale de Radiologie) with 3-MHz transducers. Both longitudinal and transversal scans were performed, and the internal diameter was expressed as the average value. Measurements were performed blindly by two observers. The intraobserver correlation was r=.96 for both observers. The interobserver correlation was r=.94 (SD=0.35 mm for AoDbif).
Arterial Wave Reflections
The effect and timing of AWR were measured noninvasively by applanation tonometry as previously described in detail. '3"14,26 The carotid pulse pressure (PP) wave was recorded with a high-fidelity Millar strain-gauge transducer (SPT-301, Millar Instruments, Inc), internally calibrated (1 mV= 1 mm Hg) with a preamplifier (TCB-500, Millar Instruments). Tonometry recordings showed a pressure wave with harmonic content close to those recorded intra-arterially, and previous studies in humans have also shown close relations between PP amplitude recorded by tonometry and pressures recorded by sphygmomanometry or by Millar catheters in the central aorta. '3,26 The carotid pressure wave was analyzed according to Murgo et al. 27 We measured the height of the shoulder (Pi, in millivolts) and the height above the shoulder (AP) of the late systolic peak (Ppk) (AP=Ppk-Pi, in millivolts) attributable to the return of wave reflections from reflecting sites (Figure) . 27 The ratio of AP to carotid PP (AP/PP) defines an augmentation index (percent) that is an estimate of the effect of wave reflections in central arteries. The time from the foot of the pressure wave to the foot of the late systolic peak (Atp) represents the travel time of the pulse wave to the peripheral reflecting site(s) and its return (Figure) . Left ventricular ejection time (LVET) was measured from the foot of the pressure wave to the diastolic incisura. The pressure waveform analysis was performed on 10 to 15 consecutive waves and done "blindly" by the same two observers. Intraobserver correlation for repeated measurements of carotid contour was excellent (r=.97 for augmentation index, with a variability of 3.7+0.7%). Interobserver reproducibility concerning the augmentation index was high (r=.96, with an interobserver difference of 4.0±1.0%). The relation between the ascending aortic pressure waveform and aortic input impedance was studied by Murgo et al. 27 An increased augmentation index is associated with an enhanced oscillatory impedance spectrum due to increased magnitude of AWR and/or interaction of reflections from different sites. PP and SBP may increase significantly from central to peripheral arteries. This contrasts with MBP, whose pressure 
Echocardiography
Two-dimensionally directed M-mode echocardiography was performed with an HP Sonos 100 (Hewlett Packard Co) using 2.5and 3.5-MHz transducers. Echocardiograms were performed by a well-trained sonographer. Measurements of left ventricular dimensions were made at end diastole according to the recommendations of the American Society of Echocardiography.28 Measurement readings were performed blindly on 5 to 10 cycles by two experienced physician readers using a digitizing tablet and were averaged. LVM was calculated by the Penn convention.29 Intrareader correlation for LVM was r=.96 for the two readers. Interreader correlation for LVM was r=.93 (mean difference, 7 g; SEM, 5.6 g). The long-term reproducibility of LVM measurements was published in a previous blinded study20 that showed that the correlation between the baseline LVM and that after 16 weeks of placebo treatment was r=.98 (mean difference, 12 g; SEM, 7 g). The fractional shortening (%Sh) was calculated from the formula [(LVEDD-LVESD)/LVEDD]x100, where LVEDD is enddiastolic and LVESD, end-systolic diameter. Mean velocity of LV fiber shortening (Vcf) was calculated as Vcf=(%Sh/ LVET). Stroke volume was calculated as the aortic annular cross-sectional area multiplied by the velocity integral of LV outflow, and cardiac output as stroke volume multiplied by heart rate. Total peripheral resistance (TPR) was computed from cardiac output (CO) and mean BP as TPR=(MBPx80)/ CO. Diastolic filling of the left ventricle was evaluated from pulsed Doppler studies obtained from the apical four-chamber view of the heart. The sample volume was positioned in the inflow area just at the tip of the mitral leaflets. Maximal early diastolic flow velocity (E) and maximal late atrial flow velocity (A) were measured and their ratio (E/A) calculated. Echocardiography was performed at the start of the study, after 6 months, and after 12 months.
Laboratory Evaluation
Blood samples were obtained after the hemodynamic study and assayed by standard methods on an autoanalyzer (RA 1000, Technicon). Ionized calcium was measured with a calcium-specific electrode (ICA2-Radiometer). Plasma renin ac- tivity, plasma aldosterone, plasma catecholamines, and parathyroid hormone level were determined by radioimmunoassay.
Statistical Analysis
The primary goal was to analyze the arterial and cardiac alterations after 1 year of follow-up. All results are reported according to an efficacy sample analysis. Data are expressed as mean+SEM. The homogeneity of the randomized groups at baseline was determined by means of an unpaired Student's t test for quantitative variables and a x2 test for qualitative variables. For comparisons of serial changes in BP, arterial hemodynamic parameters, and LVM, repeated-measures ANOVA was performed to examine treatment differences and interactions. The analysis was performed with SAS software.30
Results
Patients
Thirty-two patients were included, 16 in each group. One patient of the nitrendipine group was excluded from the study after 3 weeks of treatment for noncompliance with medication schedule, and a second patient from this group had renal transplantation after 5 weeks of treatment. After 6 weeks on active treatment, the dose of nitrendipine was increased from 20 to 40 mg/d in all patients receiving this drug. Treatment with perindopril was increased from 3 x 2 mg weekly to 3 x 4 mg weekly in 14 patients and remained unchanged (3 x 2 mg weekly) in 2 patients. Six patients (4 patients on nitrendipine and 2 on perindopril) were withdrawn from the study at 6 months because of a predialysis DBP .95 mm Hg. The 1-year study was completed by 10 patients on nitrendipine and by 14 on perindopril. Table  1 shows the baseline clinical characteristics of these two groups, which did not differ. During the course of the study, body weight, ABW, and blood chemistry remained stable and comparable in the two groups ( Table  2 ). An increase in plasma renin activity was observed in patients on perindopril (P<.05), while the other neurohumoral parameters remained unchanged ( Table 2) . No serious adverse reactions were observed with the two drugs.
BP Response
At baseline, predialysis and postdialysis supine and standing (not shown) brachial artery BPs were similar in the two groups ( Table 1) . Characteristics of the interdialytic BP monitoring are shown in Table 3 and indicate that the BP control during the 48-hour interdialytic period was achieved to a similar extent with the two drugs. BP control during scheduled visits at 3, 6, 9, and 12 months is displayed in Table 4 . Perindopril and nitrendipine decreased BP (P<.001); the effects of perindopril and nitrendipine were similar. At baseline, carotid artery BPs were similar in the two groups (Table  5 ). Both nitrendipine and perindopril decreased carotid BP (time effect, P<.001) to a similar extent (timetreatment interaction, P=NS). The decreases in carotid SBP and PP were more pronounced than those in the brachial artery, both drugs restoring the physiological amplification of peripheral SBP and PP and increasing the ratio of brachial PP to carotid PP (time effect, P<.001; time-treatment interaction, NS) ( Table 5) .
Changes in Arterial Hemodynamics
Results at baseline and at 6 and 12 months are shown in Tables 5 and 6 . Both nitrendipine and perindopril induced significant (time effect, P<.001) and similar decreases in aortic, brachial, and femoral PWVs (timetreatment interaction, NS). The decreases in PWV were similar in all arterial segments, and the transmission ratios of arm/aortic and leg/aortic PWVs remained unchanged during the study. Aortic diameters were not affected by treatment. The decrease in aortic PWV was associated with a significant increase in Atp (time effect, P<.001), which was similar with the two drugs (timetreatment interaction, NS). In parallel with the lengthening of Atp, the two drugs induced a significant (time effect, P<.001) and similar decrease in the augmentation index (time-treatment interaction, NS). The two drugs were associated with a significant (time effect, P<.001) and similar (time-treatment interaction, NS) improvement in the timing of AWR and the ventricular/ vascular coupling as shown by the decrease in the LVET/Atp and RR/Atp ratios (P<.001).
Central Hemodynamics and Echocardiographic Findings
Changes in peripheral resistance, cardiac output, and cardiac geometry are summarized in Tables 7 and 8 . Cardiac index was similar in the nitrendipine and perindopril groups at baseline and did not change significantly during the study, with unchanged stroke volume and heart rate. Total peripheral resistance at baseline was similar in the two groups and decreased significantly with each drug (time effect, P<.001; time-treatment interaction, NS). LV fractional shortening increased (time effect, P<.01) to a similar extent in both groups during the study. The E/A ratio of transmitral velocities was similar in the two groups and did not change during the study. Table 8 shows changes in LVM and cardiac dimensions of patients treated for 1 year. Patients had, at baseline, near-normal mean LV wall thickness, and the increased LVM was due primarily to an increase in LVEDD. Such a pattern of LVH is more compatible with volume overload, but in the overall population, a weak but significant correlation was observed between systolic BP and LVM index (r=.489; P=.015). Compared with baseline, 12 months of nitrendipine treatment did not significantly influence LVM, which decreased by only 28+13 g, or 9+5%. On the other hand, perindopril treatment was associated with an LVM reduction of 70+11 g, ie, 22±3% (time-treatment inter- 
Discussion
To the best of our knowledge, the present study is the first controlled, blinded study to directly compare the differential effects of antihypertensive drugs on arterial hemodynamics and LVM in ESRD patients. The results indicate that after 12 months of converting enzyme inhibition and calcium channel blockade, important dissociations are observed between the antihypertensive effect and the arterial and cardiac changes produced by these agents. Although the two treatments had similar effects on BP and determinants of aortic input impedance, prolonged treatment with perindopril reduced LVH in ESRD patients, whereas nitrendipine did not. The cardiac effect of perindopril was principally due to reduction of LV dilatation and decrease in LV diameter.
Chronic pressure overload and hypertension are considered to be important hemodynamic factors contributing to the development of LVH in the general population and in patients with ESRD.5-710 Classically, the degree of LVH is related to systemic BP and vascular resistance levels and hence to the degree of small-artery constriction.31 However, hemodynamic load is a much more complex phenomenon, vascular resistance being only one determinant of the ventricular afterload. Other determinants of aortic input impedance, ie, aortic distensibility and diameter, and the intensity and timing of AWR32 also interact with the left ventricle and have an important role in determining the development of LVH. 32, 33 In ESRD patients, decreased aortic distensibility and increased effect of wave reflections were associated with LVH independent of the BP level and of changes in peripheral resistance. 12, 14 Studies in essential hypertensive patients with echocardiographically determined LVH revealed that the same BP control with different antihypertensive drugs was not consistently associated with reduction of LVM.34 These disparate effects of different classes of antihypertensive agents on LVM could be a result of their different actions on vascular resistance and the other determinants of aortic input impedance. 35 Indeed, it has been shown that, for the same BP-lowering effect at the brachial artery, antihypertensive drugs that decreased the intensity and improved the timing of wave reflections had a greater effect on BP in central arteries, thus decreasing end-systolic stress to a greater extent. 36 It has also been demonstrated that not all antihypertensive agents increase aortic and arterial distensibility, despite equivalent effects on brachial BP and total vascular resistance. 37 Nevertheless, such differential action on aortic input impedance cannot account for the different effects of nitrendipine and perindopril on LVM observed in the present study.
In the present study, perindopril and nitrendipine ensured a similar control of BP and had comparable effects on the vascular determinants of ventricular af-terload. They both decreased peripheral resistance, increased arterial compliance, and decreased the effect and improved the timing of wave reflections. They also decreased carotid SBP and PP to a greater extent than brachial SBP and PP and restored the peripheral SBP and PP amplification. The principal determinants of the magnitude of centrifugal PP amplification in physiological conditions are (1) the discontinuity in impedance of successive arterial segments (related to the progressive centrifugal decrease in compliance and diameters of the arterial system)'1,32 and (2) the intensity and timing of wave reflections. With the two drugs used in the present study, the distensibilities of the aorta and peripheral arteries changed in parallel and to a similar extent, with unchanged transmission ratios and aortic diameters. In these conditions, it is improbable that the drugs induced an increase in the impedance discontinuity of large arteries, which is responsible for peripheral pressure amplification. Since both drugs decreased vascular resistance, the peripheral pressure amplification cannot be explained by peripheral vascular mismatch. The peripheral pressure amplification also depends on the propagative properties of the vascular system, which determine the time taken for the pressure waves to travel to and from the peripheral sites back to central arteries and thus the timing of incident and reflected waves.27 Timing of wave reflections depends on arterial distensibility (determinant of PWV) and on body length (determinant of arterial length and the distance of the reflecting sites).1"4327.32 The decreased effect of wave reflections on the central arterial pressure wave after perindopril and nitrendipine was associated with increased arterial compliance and decreased PWV, which are responsible for an increased travel time (Atp) and a delayed return of reflected waves. An increased Atp is characteristic of a frequency shift of the first minimum (fmin) of impedance modulus [fmin= 1/(2lAtp)]27 to lower frequencies. The coupling of LV ejection to its hydraulic load would be optimized when the lower harmonics of the flow wave (corresponding to heart frequency) occur close to the frequency of fmin.11"32 Perindopril and nitrendipine decreased the RR/Atp and LVET/Atp ratios, suggesting an improvement in the timing of wave reflections and ventricular-vascular coupling.
Nevertheless, despite the decreased PWV and the decreased effect of wave reflections on central BP with perindopril and nitrendipine, the augmentation index remained higher and the Atp shorter than values that would be observed in nonuremic subjects of the same age and BP.13 This should be attributed to two factors: (1) the still higher PWV (in comparison to pressureand age-matched nonuremic subjects) due to the accelerated arterial aging observed in ESRD patients12 and (2) the shorter body height of ESRD patients,13 which of course was not influenced by antihypertensive drugs. The persistence of a greater effect of wave reflections accounts for the persistence of higher than normal SBP and PP despite normalization of DBP.
The improvement in the function of the resistance and conduit arteries can be related to decrease in the vascular smooth muscle tone and/or to changes in the structure and geometry of the vessel. In spontaneously hypertensive rats treated with different antihypertensive therapies, Christensen38 showed that perindopril and the dihydropyridine calcium blocker isradipine decreased the media-to-lumen ratio of mesenteric resistance arteries, with perindopril also increasing the lumen diameter. In humans, Heagerty et a139 and Aalkjaer et a140 found that long-term antihypertensive treatment in patients with essential hypertension reduced the media thickness and media-to-lumen ratio of resistance arterioles but did not fully normalize the structure of resistance arteries. More recently, in a double-blind randomized study, Schiffrin et a141 tested the effects of ACE inhibitors and fl-blockers on subcutaneous resistance arteries in humans. After 1 year of treatment, for the same BP-lowering effect, the ACE inhibitor (but not the /-blocker) reduced and partly corrected the mediato-lumen ratio and corrected the functional abnormalities of resistance vessels. These studies did not address the effects of antihypertensive drugs in uremic patients, but studies of subcutaneous resistance arteries in ESRD patients on hemodialysis have shown functional and morphological alterations similar to those observed in essential hypertensive patients. 42 The question concerning the functional versus structural origin of the improvement in arterial compliance and distensibility, as characterized by decreased PWVs, is difficult to answer. The decrease in PWV observed with the two drugs paralleled those in BP and peripheral resistance, and the improvement in arterial disten- sibility could simply be the mechanical consequence of the decrease in distending pressure and arteriolar vasodilation, or it could reflect intrinsic functional or structural alterations of the arterial wall.11 '32 In vivo experimental studies in animal models of renovascular and essential hypertension have shown that both ACE inhibitors and dihydropyridine calcium channel blockers improve large artery compliance independently of BP changes43-45 after both acute and chronic administration. This improvement in arterial compliance was related to vascular smooth muscle cell relaxation and to decreased arterial wall thickness with the reversion of smooth muscle cell hypertrophy.43-45 On the other hand, it has been shown that the long-term administration of ACE inhibitor prevents the increase in aortic collagen content in spontaneously hypertensive rats in a nonpressure-dependent manner,46 and long-term treatment with a dihydropyridine calcium entry blocker reduced arterial wall collagen content in both hypertensive animals and normotensive Wistar-Kyoto rats. 45 The contributions of decreased BP or of intrinsic arterial wall alterations to improved arterial distensibility with antihypertensive drugs are more difficult to evaluate in humans. In patients with sustained essential hypertension, acute and long-term administration of ACE inhibitors and calcium channel blockers caused a significant increase in carotid and brachial artery diameters. Since such effects were observed in the presence of a significant reduction of distending BP, it appears that the mechanical effects of BP reduction (ie, decrease in diameter) were offset by the arterial dilating effect of the antihypertensive drugs. 35, [47] [48] [49] [50] [51] In addition to the increased arterial diameter, a significant increase in arterial distensibility has also been observed after ACE inhibition.4849 After perindopril administration in es-sential hypertensive humans, the increase in arterial compliance was not associated with a change in tangential tension of the arterial wall, which supports the role of intrinsic BP-independent alterations.49 Similarly, in patients with sustained hypertension, acute and longterm administration of dihydropyridine derivatives caused a significant increase in brachial artery diameter and in arterial compliance.4750-5' In a double-blind, placebo-controlled, randomized study in hypertensive patients with ESRD,20 nitrendipine given for 24 weeks induced a significant decrease in aortic and femoral PWV unrelated to any change in aortic diameter, since this parameter remained constant. During the first 8 to 16 weeks of treatment, the decrease in PWV paralleled the decrease in BP. The aortic PWV continued to decrease until the end of the trial at week 24, but these late changes in aortic distensibility were no longer related to antihypertensive effect, which remained constant, suggesting that the long-term improvement of arterial distensibility could be related to changes in elastic modulus, wall thickness, or both. In renovascular and spontaneously hypertensive rats, perindopril significantly decreased LVM, decreased arterial wall thickness, and increased arterial distensibility.4344 This contrasted with the long-term effects of the calcium channel blocker isradipine, which improved arterial distensibility and reduced arterial wall thickness but had no effect on LV hypertrophy.45 Similar arterial but different cardiac effects with the two classes of drugs were observed in the present clinical study. Perindopril was associated with improved arterial hemodynamics and decreased LVM, whereas nitrendipine improved arterial hemodynamics but had no significant effect on LVH. Numerous reports describe regression of LVH with various pharmacological agents. These data sug- gest that ACE inhibitors, 1-blockers, and nondihydropyridine calcium channel antagonists reduce LVM, whereas diuretics and peripheral vasodilators are less effective.3-5 In humans, the reports in the literature concerning the effects of dihydropyridines on regression of LVH are contradictory; both reduction of and no effect on LVM have been reported.20 '52-55 In agreement with a previous controlled study in patients with ESRD,20 the present study indicated that nitrendipine does not decrease LVM despite improved BP control and arterial function. Indeed, 12 months of treatment with nitrendipine was associated with only a 9% reduction in LVM; this change was insignificant, and, as proposed by Koren and Devereux,34 should be considered as within the range of the variability of these measurements. The fact that drugs with the same effect on peripheral resistance and arterial hemodynamics had different effects on LVM suggests that mechanisms other than alterations in ventricular afterload played a role in the observed regression of LVH in ESRD patients.
In addition to pressure overload, cardiac volume overload participates in the genesis of LVH in patients with ESRD, and most of these patients have an increase in LV cavity dimensions and volume compatible with eccentric hypertrophy. Such a pattern of LV hypertrophy was also observed in the present study, and the principal echocardiographic parameter associated with the decrease in LVM in ESRD patients receiving perindopril was a decrease in LV "dilatation," as characterized by the reduction in LVEDD. This observation is similar to those made in nonuremic patients with depressed LV ejection fraction and ventricular dilatation.5657 Indeed, in patients enrolled in the SOLVD treatment and prevention trial, the progressive LV dilatation in patients with LV dysfunction was prevented or reversed by administration of ACE inhibitor. The present study indicates that similar regression of LV dilatation can be observed in patients with normal ventricular function. The decreases in internal dimensions of the left ventricle and of LV end-diastolic pressure58 with ACE inhibitors are responsible for a decrease in end-diastolic myocardial wall stress and preload. The principal factors related to the LVEDD and associated with LV dilation in ESRD patients are chronic flow overload and increased preload due to anemia, overhydration, and arteriovenous shunts.5-7 Anemia correction with human recombinant erythropoietin has been shown to decrease LV diameter and lead to partial regression of LVH.59,60 Although the degree of volume overload (anemia, ABW, and overhydration) in the present study was similar in the two treatment groups, the effect of the two treatments on how the volume load was presented to the LV was probably not. The relation between the volume load and cardiac filling is critically dependent on the capacitive properties of the vascular system, especially the compliance of the low-pressure venous system.61.62 Using an experimental model of rats with large myocardial infarctions, Raya et a163 showed that ACE inhibitor prevention of LV dilatation occurs via both afterload reduction and also significant venodilatation and increased venous compliance. Reduced venous compliance is observed in hypertensive hemodialysis patients.64 It cannot be reversed by acute administration of nitroglycerin or a1sympatholytic agents and is related to structural factors with increased venous media thickness and medial smooth muscle hypertrophy. It is possible that chronic administration of perindopril in ESRD patients altered the structural and functional properties of the venous system and increased its capacitance, but this was not evaluated in the present study.
It seems improbable that the regression of LVM after perindopril was the consequence of blockade of the circulating renin-angiotensin system. The circulating reninangiotensin system exerts short-term regulation on cardiovascular homeostasis,65 and while this system influences the vasomotor tone of the arterial system, the vasorelaxant effects of perindopril and nitrendipine were the same in this study. Furthermore, the changes in LVM were not related to baseline plasma renin activity or to changes in plasma renin activity after treatment. Multiple lines of evidence have shown that the heart is capable of generating angiotensin II locally, and it has been shown that angiotensin II directly stimulates cardiac myocyte hypertrophy.66.67 It is also known that renin-angiotensin system blockade can alter the secretion of aldosterone, whose role in the pathogenesis of myocardial fibrosis and LVH has been underlined.68 However, perindopril did not alter plasma aldosterone levels significantly (in relation to the hyperkalemia and alterations in potassium homeostasis in ESRD) in these dialysis patients, making the role of reduced aldosterone in the decrease of LVH improbable. Finally, blockade of the renin-angiotensin system could also modulate the reactivity and release of catecholamines,69 which could have a direct trophic influence on myocardial growth. In the present study, plasma catecholamine concentrations remained unchanged after ACE inhibitor administration, which does not support this possibility. In patients treated with nitrendipine, plasma norepinephrine concentration increased slightly over time, but the plasma levels remained similar to those of patients treated by perindopril.
Despite their different effects on LVM, both drugs produced only moderate and similar effects on the indexes of LV systolic function, probably because the baseline indexes of LV function were normal. The only changes observed were an increased fractional shortening and increased velocity of circumferential fiber shortening. Regression of LVH with perindopril did not compromise systolic function of the left ventricle. Indexes of diastolic filling were within the normal range at baseline and did not change in the course of the study (E/A ratio unchanged).
The principal limitation of the present study concerns the small number of subjects studied and the relatively short follow-up necessary to assess the effect of dihydropyridines on the LVH in ESRD patients. Nevertheless, present data confirm those previously observed in a larger group of ESRD patients treated with nitrendipine versus placebo, which showed similar improvement of arterial distensibility and absence of regression of LVH.20
In conclusion, this study shows that treatment of ESRD patients with LVH by a dihydropyridine calcium channel blocker or an ACE inhibitor results in cardiac and arterial changes that can be dissociated from each other and from the antihypertensive effect. The dihydropyridine nitrendipine did not decrease LVM despite decreasing left ventricular afterload. In contrast, the ACE inhibitor perindopril, which induced similar changes in BP control and arterial function, also induced a significant decrease in LVM. The decrease in LVM was principally associated with a reduction of the LVEDD, indicating that perindopril also decreased the LV preload associated with volume and flow overload present in these patients. In patients receiving perindopril, diastolic and systolic ventricular functions were preserved after regression of the hypertrophy. However, the long-term impact of reduction of LVH on the cardiovascular mortality and morbidity in ESRD patients remains to be evaluated.
